- Home
- RIGL vs PRTA Comparison
RIGL vs PRTA Comparison
Compare RIGL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- PRTA
- Stock Information
- Founded
- RIGL 1996
- PRTA 2012
- Country
- RIGL United States
- PRTA Ireland
- Employees
- RIGL N/A
- PRTA N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- PRTA Health Care
- Exchange
- RIGL Nasdaq
- PRTA Nasdaq
- Market Cap
- RIGL 335.5M
- PRTA 472.1M
- IPO Year
- RIGL 2000
- PRTA N/A
- Fundamental
- Price
- RIGL $38.85
- PRTA $8.20
- Analyst Decision
- RIGL Buy
- PRTA Buy
- Analyst Count
- RIGL 5
- PRTA 10
- Target Price
- RIGL $38.20
- PRTA $14.86
- AVG Volume (30 Days)
- RIGL 995.6K
- PRTA 1.2M
- Earning Date
- RIGL 08-05-2025
- PRTA 08-04-2025
- Dividend Yield
- RIGL N/A
- PRTA N/A
- EPS Growth
- RIGL N/A
- PRTA N/A
- EPS
- RIGL 5.43
- PRTA N/A
- Revenue
- RIGL $267,921,000.00
- PRTA $10,341,000.00
- Revenue This Year
- RIGL $59.93
- PRTA N/A
- Revenue Next Year
- RIGL N/A
- PRTA $389.77
- P/E Ratio
- RIGL $7.15
- PRTA N/A
- Revenue Growth
- RIGL 105.62
- PRTA N/A
- 52 Week Low
- RIGL $12.66
- PRTA $4.32
- 52 Week High
- RIGL $43.72
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- PRTA 58.73
- Support Level
- RIGL $39.00
- PRTA $8.05
- Resistance Level
- RIGL $42.08
- PRTA $8.73
- Average True Range (ATR)
- RIGL 2.32
- PRTA 0.38
- MACD
- RIGL -0.37
- PRTA -0.05
- Stochastic Oscillator
- RIGL 53.26
- PRTA 47.62
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.